- Home
- IBRX vs APLS Comparison
IBRX vs APLS Comparison
Compare IBRX & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- APLS
- Stock Information
- Founded
- IBRX 2014
- APLS 2009
- Country
- IBRX United States
- APLS United States
- Employees
- IBRX N/A
- APLS N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- IBRX Health Care
- APLS Health Care
- Exchange
- IBRX Nasdaq
- APLS Nasdaq
- Market Cap
- IBRX 2.3B
- APLS 2.2B
- IPO Year
- IBRX N/A
- APLS 2017
- Fundamental
- Price
- IBRX $2.81
- APLS $19.35
- Analyst Decision
- IBRX Strong Buy
- APLS Buy
- Analyst Count
- IBRX 5
- APLS 19
- Target Price
- IBRX $11.40
- APLS $37.39
- AVG Volume (30 Days)
- IBRX 7.3M
- APLS 1.9M
- Earning Date
- IBRX 08-11-2025
- APLS 07-31-2025
- Dividend Yield
- IBRX N/A
- APLS N/A
- EPS Growth
- IBRX N/A
- APLS N/A
- EPS
- IBRX N/A
- APLS N/A
- Revenue
- IBRX $31,222,000.00
- APLS $775,839,000.00
- Revenue This Year
- IBRX $567.98
- APLS $1.01
- Revenue Next Year
- IBRX $160.56
- APLS $22.14
- P/E Ratio
- IBRX N/A
- APLS N/A
- Revenue Growth
- IBRX 10238.41
- APLS 48.04
- 52 Week Low
- IBRX $1.83
- APLS $16.10
- 52 Week High
- IBRX $7.48
- APLS $42.47
- Technical
- Relative Strength Index (RSI)
- IBRX 51.33
- APLS 59.31
- Support Level
- IBRX $2.68
- APLS $17.35
- Resistance Level
- IBRX $3.00
- APLS $19.63
- Average True Range (ATR)
- IBRX 0.16
- APLS 0.76
- MACD
- IBRX -0.00
- APLS 0.19
- Stochastic Oscillator
- IBRX 62.00
- APLS 93.47
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.